
Achondroplasia Trial Shows Growth Gains in Children
Children treated with the investigational oral therapy infigratinib saw their growth rates increase by 2.10 centimeters per year compared to those given a placebo. The global Phase 3 trial, involving 114 participants, marks a significant shift in addressing the underlying biological drivers of the most common form of dwarfism.

























